Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

This study is testing whether combining pembrolizumab (an immunotherapy drug) with a specific type of radiation (hypofractionated radiation — a higher dose delivered over fewer sessions) can improve outcomes after surgery for mucosal melanoma, a rare type of melanoma that forms inside the body on moist surfaces (such as the mouth, nasal passages, or genitals). **You may be eligible if...** - You are at least 16 years old - You have mucosal melanoma that has been surgically removed - You have not received prior radiation therapy at the area being treated - You are in reasonably good physical condition (ECOG performance status 0, 1, or 2) - Your blood counts, liver function, and kidney function are within required ranges - You agree to use contraception during and after treatment **You may NOT be eligible if...** - You have previously been treated with pembrolizumab or similar immunotherapy drugs - You have active autoimmune disease - You are on immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.